Publikationen in Zusammenarbeit mit Forschern von University of Hull (8)

2024

  1. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  2. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 5, pp. 771-778

  3. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial

    European Journal of Heart Failure, Vol. 24, Núm. 9, pp. 1559-1568

2021

  1. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

    JACC: Heart Failure, Vol. 9, Núm. 4, pp. 268-277

  2. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

    European Heart Journal, Vol. 42, Núm. 6, pp. 684-696

2017

  1. Risk for incident heart failure: A subject-level meta-analysis from the heart "OMics" in AGEing (HOMAGE) study

    Journal of the American Heart Association, Vol. 6, Núm. 5

2014

  1. Heart 'omics' in AGEing (HOMAGE): Design, research objectives and characteristics of the common database

    Journal of Biomedical Research, Vol. 28, Núm. 5, pp. 349-359